Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.41 |
| ▸ | ST6GAL1 | P15907 | 7/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19834674 | 1.00 | CYP3A4 (0.50) | CYP3A4CYP2C9BTN3A1ST6GAL1POLA1 | |
| SCHEMBL18125651 | 1.00 | CYP3A4 (0.50) | CYP3A4CYP2C9BTN3A1ST6GAL1POLA1 | |
| SCHEMBL19834673 | 1.00 | CYP3A4 (0.50) | CYP3A4CYP2C9BTN3A1ST6GAL1POLA1 | |
| SCHEMBL19847457 | 1.00 | CYP3A4 (0.50) | CYP3A4CYP2C9BTN3A1ST6GAL1POLA1 | |
| SCHEMBL19834662 | 0.94 | CYP3A4 (0.44) | CYP3A4CYP2C9BTN3A1ST6GAL1POLA1 | |
| SCHEMBL18125664 | 0.94 | CYP3A4 (0.44) | CYP3A4CYP2C9BTN3A1ST6GAL1POLA1 | |
| SCHEMBL19834664 | 0.94 | CYP3A4 (0.44) | CYP3A4CYP2C9BTN3A1ST6GAL1POLA1 | |
| SCHEMBL17725031 | 0.94 | CYP3A4 (0.43) | CYP3A4CYP2C9BTN3A1ST6GAL1POLA1 | |
| SCHEMBL19834666 | 0.94 | CYP3A4 (0.45) | CYP3A4CYP2C9BTN3A1ST6GAL1POLA1 | |
| SCHEMBL19834663 | 0.94 | CYP3A4 (0.45) | CYP3A4CYP2C9BTN3A1ST6GAL1POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11266674-B2 | Pharmaceutical composition for tumor treatment or prevention, method, and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-03-08 | — | — | US | disclosed |
| EP-3677267-A1 | PHARMACEUTICAL COMPOSITION FOR TUMOR TREATMENT OR PREVENTION, METHOD, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-07-08 | — | — | EP | disclosed |
| US-10662214-B2 | Compound of 4′-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof | Sichuan Keiun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-20200121707-A1 | PHARMACEUTICAL COMPOSITION FOR TUMOR TREATMENT OR PREVENTION, METHOD, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-04-23 | — | — | US | disclosed |
| US-10059734-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | FUJIFILM CORPORATION (JP) | 2018-08-28 | — | — | US | disclosed |
| US-20180079770-A1 | NOVEL COMPOUND OF 4'-THIONUCLEOSIDE, AS WELL AS PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-03-22 | — | — | US | disclosed |
| EP-3279207-A1 | NOVEL COMPOUND OF 4'-THIONUCLEOSIDE, AS WELL AS PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2018-02-07 | — | — | EP | disclosed |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662214-B2 | Compound of 4′-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof | TYMP, WEE1, NTPCR | CYP3A4 2879/4885CYP2C9 4543/4885BTN3A1 1826/4885 |
| US-20180079770-A1 | NOVEL COMPOUND OF 4'-THIONUCLEOSIDE, AS WELL AS PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | WEE1, WEE2, THEM6 | CYP3A4 3333/4885CYP2C9 4768/4885BTN3A1 1269/4885 |
| US-20200121707-A1 | PHARMACEUTICAL COMPOSITION FOR TUMOR TREATMENT OR PREVENTION, METHOD, AND USE THEREOF | TP53, PHOSPHO1, TTR | CYP3A4 1685/4885CYP2C9 2457/4885BTN3A1 4341/4885 |
| US-11266674-B2 | Pharmaceutical composition for tumor treatment or prevention, method, and use thereof | TP53, PHOSPHO1, TTR | CYP3A4 1685/4885CYP2C9 2457/4885BTN3A1 4341/4885 |
| US-10059734-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | SLC11A2, RNASE1, TYMP | CYP3A4 3906/4885CYP2C9 3818/4885BTN3A1 4350/4885 |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | SLC11A2, RNASE1, TYMP | CYP3A4 3906/4885CYP2C9 3818/4885BTN3A1 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.